Ferro Corp., of Cleveland, sold its pharmaceuticals business, Pfanstiehl Laboratories, to PLI Holdings Inc., an affiliate of Med Opportunity Partners LLC, for $16.9 million in cash and an earn-out incentive payment of up to $8 million, payable over two years based on earnings targets...The move is part of a strategy by Ferro to divest non-core businesses and drive growth from its Performance Materials and Performance Chemicals businesses...The exchange offer is being carried out to satisfy obligations
to explore strategic options for Stedivaze, a highly selective adenosine A2A agonist in development as a pharmacological stress agent for use in myocardial perfusion imaging...The company plans to use the funding to advance its vaccine candidate, designed to block transmission against malaria...The company's technology fuses candidate vaccine antigens from malaria to self-assembling proteins from the ciliated protozoan, Tetrahymena, to create nanometer-sized particles called G-Somes that have the
The company's board of directors approved the implementation of a reverse stock split and determined the appropriate reverse stock split ratio to be a ratio of 1-for-7 on March 22
DSP will exclusively discuss with RIJ to collaborate in and outside Japan...RIJ said it aims to commercialize the world's first pharmaceutical iPS cell-derived retinal pigment epithelial cells...Completion of the rights sale under the APA is subject to certain third-party and Chinese regulatory approvals
Omeros said it plans to submit an application in Europe to start clinical trials in the second quarter...In other news, SCT closed its previously announced private placement for gross proceeds of C$3.2 million (US$3.1 million
The agreement allows the HPA to contribute to global polio eradication, while securing a commitment from a major pharma firm to develop use of its technology...Terms include certain milestones and tiered royalty payments to the HPA in return for technology transfer and other licensing rights
Eisai Inc., of Woodcliff Lake, N.J., said the FDA approved Aciphex Sprinkle delayed-release capsules for the treatment of gastroesophageal reflux disease in children, ages 1 to 11, for up to 12 weeks
Ltd., of Yokohama, Japan, to use its cell-loading system to support clinical studies and commercialize treatment of cancer patients...The new partners plan to start clinical trials following an investigational new drug application later this year...Themis plans to start Phase I for both vaccines before the end of this year
The manufacturing center will afford GSK the capabilities to eventually manufacture influenza vaccine based on a cell culture line...A pivotal program of Lu AE58054 is planned to start later this year, starting with a Phase III study in patients with mild to moderate Alzheimer's disease testing Lu AE58054 as an adjunct treatment to donepezil
The product is designed to neutralize IL20 and IL22, which are involved in proliferation and differentiation of keratinocytes and are implicated in autoimmune diseases of the skin such as atopic dermatitis and psoriasis...ARGX-112 is the fourth program to progress to the preclinical stage in 40 months since the start of company operations...The company said it intends to request an end-of-review meeting with the FDA
Under terms of the agreement, Actavis can launch its generic version of Crestor 67 days prior to July 8, 2016, the expiration of pediatric exclusivity, at a fee of 39 percent of net sales to AstraZeneca...The FDA granted tentative approval to Actavis' ANDA on June 6, 2011
Deinove's contribution to the subsidiary are the results and intellectual property rights relating to research undertaken on antibiotics, as well as the transfer of the OSEO-ERDF-LR region funding already allocated – €700,000 (US$908,857...would entitle pSivida to a $25 million milestone payment from Alimera and 20 percent of net profits
In separate news, Astellas signed a deal to access the TSUBAME2.0 supercomputer at the Tokyo Institute of Technology to discover candidates for NTDs caused by dengue virus
Cancer Research Technology, the commercial arm of Cancer Research UK, and the Institute of Cancer Research, London, said they were collaborating with Janssen Biotech Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, to discover a potential new multiple myeloma drug
Another $13 million to $15 million in equipment, integration service and testing will be provided by Agila...The resolution would authorize the board to effect a share consolidation at a rate of up to 10 to 1...The compounds are thought to have relevance for Parkinson's disease
The FDA stated that bleeding rates associated with new use of Pradaxa do not appear to be higher than those with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial
Sosei licensed Japanese rights to the compound from BioAlliance, which markets the product as Loramyc/Oravig...The studies are designed to allow PCT to evaluate the applicability of SistemQC technology in stem cell characterization employing Sistemic's miRNA profiling system and analytical approaches to product miRNA panels
BioWorld International | Wednesday, March 20, 2013
The parties agreed to a settlement payment of $40 million, $38 million of which will be funded by Dendreon's insurers...sales and distribution rights to Abstral (fentanyl) sublingual tablets from Orexo AB, of Uppsala, Sweden...An independent assessment to confirm the diagnosis and evaluate the cause is planned
Save for Wolbern Private Equity GmbH (WPE), no other partner who took part in the formal sale process made an offer, and WPE later withdrew its offer...Ark has been struggling to keep itself afloat since 2010, when the European Medicines Agency rejected gene therapy candidate Cerepro for use in glioma...Vanda said it intends to reassess its European regulatory strategy once those results become available
Ferro Corp., of Cleveland, sold its pharmaceuticals business, Pfanstiehl Laboratories, to PLI Holdings Inc., an affiliate of Med Opportunity Partners LLC, for $16.9 million in cash and an earn-out incentive payment of up to $8 million, payable over two years based on earnings targets...The move is part of a strategy by Ferro to divest non-core businesses and drive growth from its Performance Materials and Performance Chemicals businesses...The exchange offer is being carried out to satisfy obligations